A922 Sequential measurement of 1 hour creatinine clearance (1-CRCL) in critically ill patients at risk of acute kidney injury (AKI)

Meeting abstrac

Nurses' perceptions of aids and obstacles to the provision of optimal end of life care in ICU

Contains fulltext : 172380.pdf (publisher's version ) (Open Access

FACTORS ASSOCIATED WITH THE DEVELOPMENT OF ANTI-DRUG ANTIBODIESTOTUMOUR NECROSIS FACTOR INHIBITORS IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS; A TWOYEAR FOLLOW-UP STUDY

[No Abstract Available

AB0643 Are there any distinctive finding in ANCA-associated vasculitis related pulmonary involvement in comparison with Connective Tissue Diseae or Idiopatic pulmonary fibrosis

BackgroundPatients with ANCA associated vasculitis (AAV) have a wide spectrum of pulmonary involvement from parenchymal necrotizing granuloma formation, trecheobronchial inflammation, pulmonary capillaritis to interstitial lung disease. Pulmonary involvement is relatively common in connective tissue diseases (CTDs). Both rheumatologic disorders and idiopatic pulmonary fibrosis (IPF) might cause the usual interstitial pneumonia (UIP) pattern. However, little is known regarding the clinical and radiologic similarities/ dissimilarities of those diseases.ObjectivesWe aimed to evaluate the thoracic computed tomography (CT) findings of patients with AAV, CTDs-related interstitial lung disease (ILD) or IPF.MethodsPatients whose thoracic CT performed at the time of the diagnosis or relapse of AAV (n=64), at the time of the diagnosis of CTD related ILD (n=55) or IPF (n=52) were included in the analysis. Demographic, clinical and serological data were collected retrospectively. Radiological patterns of pulmonary involvement were evaluated by two expert pumonary radiologists and abnormal thoracic CT findings were classified according to Fleischner Society guidelines. Intra- and inter-observer variation were calculated. Multoniminal logistic reggresion was performed to identfy disease specific findings in thoracic CT.ResultsA total of 171 patients were included and of them 64 patients (62.5% with granulomatosis with polyangiitis, 37.5% with microscopic polyangiitis) in AAV group, 55 patients in CTD related ILD (50.9% with scleroderma, 40.0% with rheumatoid arthritis, 9.1% other or undifferensiye connective tisue disease) group and 52 patients in IPF group. Demographic and thoracic CT findings were summarized in Table 1. In univariate analysis according to Fleishner Society definition, patients with AAV had more common pulmonary noduls, cavities, consolidation. However, patients with AAV were less likely to have interlobular septal thickening (ILST), lymph node adenopathy (LAP) and reticulation compared to both CTD related ILD and IPF. In addition, among those groups of rheumatic diseases, cavities and alveolar hemorrhage were detected only AAV. In multinominal logistic reggresion, the presence of nodul and consolidation and the absence of ILST and mediastinal LAP were independent determinant findings in thoracic CT in patients with AAV in comparison with both CTD related ILD or IPF.Table 1.Demoraphic characteristics and Thoracic CT findings of patientsAAV patients (n=64)CTD related ILD (n=55)IPF (n=52)pCharacteristicsAge at diagnosis, yrs, mean (SD)58.6 (15.0)61.8 (12.0)72.4 (9.4)&lt;0.001Sex, male, %70.330.975&lt;0.001Smoking, ever, %77.826.562.80.29Chest CT findings according to Fleishner guideline, %Ground glass opasity29.738.29.60.003Reticulation19.052.794.2&lt;0.001Interlobular septal thickening28.669.198.1&lt;0.001Peribronchial thickening11.120.03.80.03Honeycombing14.325.563.5&lt;0.001Bronchiectasis31.347.386.5&lt;0.001Consolidation45.312.75.8&lt;0.001Micronodules6.33.600.07Nodules45.310.93.8&lt;0.001Cavities23.400&lt;0.001Eymphysema18.87.319.20.96Mosaic attenuation pattern7.82038.5&lt;0.001Alveolar hemorrage17.200&lt;0.001Mediastinal lymph node adenopathy26.753.757.70.002Pleural effusion14.11.800.001Pericardial effusion6.39.100.16ConclusionThe results of this study show that in additon to clinical and labaratory characteristics, some thoracic CT imaging findings like the presence of nodules and consolidation and the abscence of LAP and ILST may be useful to differentiate pulmonary involvement of AAV from other relatively common rheumatologic conditions and IPF. In addition, alveolar hemorrhage and cavities may be particular manifestations of AAV.Disclosure of InterestsNone declared</jats:sec

AB0657 IMPROVEMENT IN DISEASE ACTIVITY IS ASSOCIATED WITH ENHANCEMENT IN THE QUALITY OF LIFE DURING TUMOUR NECROSIS ALPHA INHIBITOR TREATMENT; A PROSPECTIVE COHORT EXPERIENCE IN AXIAL SpA

Background:Axial spondyloarthritis (axSpA) is a chronic inflammatory condition affecting mainly axial skeleton. The disease usually starts in early adulthood and cause considerable impact on physical function, work ability and quality of life (QoL). With the introduction of tumour necrosis factor inhibitors (TNFi) significant improvement in articular and extra-articular manifestations of disease was shown in randomized controlled trials and several registries. However, there is limited data about the effects of TNFi therapy on QoL and the relationship between inflammation and QoL in cohort studies before.Objectives:To evaluate the influence of TNFi agents on different aspects of QoL which might be a significant determinant of patient burden in axSpA patients in parallel with disease activity.Methods:In total 83 TNFi naïve axSpA patients (62.7% male; mean age 40.6 ± 12 years) according to the ASAS criteria were included in this prospective observational cohort study between 2014-2018. Demographic and disease related characteristics were collected at baseline. Disease activity (BASDAI, ASDAS-CRP), function (BASFI) and QoL (SF-36 and ASQoL) were evaluated at baseline and 24thand 52ndweeks of follow-up. The changes in disease activity, function and QoL were assessed with Wilcoxon test and relationship between changes in QoL and activity on week 24 was evaluated by Spearman’s correlation analysis.Results:Baseline disease related characteristics, disease activity and QoL scores were presented in table 1. Both disease activity and QoL were significantly improved at 24thand 52thweeks (Figure 1). The change of SF-36 subscales and summary scores at weeks 24 were correlated with the change in disease activity and function (Table 2). The SF-36 scale and summary scores were found to be similar at 24 and 52 weeks of TNFi treatment (Figure 2).Conclusion:The results of the present study suggest that TNFi treatment have a substantial influence on QoL in parallel to the control of disease activity at 24thweeks of treatment and this effect was sustained at 52 weeks not only randomized controlled trials but also real life experience.Table 1.Demographic and clinical features in patients with axial spondyloarthritis at baselineParametersDuration of disease, years*9 (10)Ever smoking, n(%)36 (43.4)Body mass index, kg/m2 *26 (4.9)HLA-B27 positivity, n(%)39/57 (68)Peripheral arthritis, n(%)39 (47)BASFI*5.1 (2.3)BASDAI*5.8 (1.7)ASQOL*12 (8)ASDAS-CRP*3.6 (1.1)PCS*32.5 (7.9)MCS*37.3 (10.9)*All parameters presented as mean (SD)Table 2.Correlation with changing of disease activity scores and quality of life parameters at 24 weeksΔBASDAIΔBASFIΔASDAS-CRPΔASQOLprprPrprΔPCS&lt;0.001-.60&lt;0.001-.43&lt;0.001-.45.002-.39ΔMCS.001-.42.012-.31.019-.29&lt;0.001-.50ΔPF&lt;0.001-.48&lt;0.001-.52.008-.31.021-.28ΔRP&lt;0.001-.48.028-.25.001-.38.002-.35ΔBP&lt;0.001-.60.004-.33&lt;0.001-.45&lt;0.001-.46ΔGH&lt;0.001-.58.026-.27&lt;0.001-.45&lt;0.001-.54ΔVT&lt;0.001-.48.001-.39.004-.33.003-.34ΔSF.001-.38.064-.21.098-.19.008-.31ΔRE.003-.34.013-.28.012-.29.004-.34ΔMH.003-.34.016-.28.044-.23&lt;0.001-.43BASDAI Bath Ankylosing Spondylitis Activity Index; BASFI Bath Ankylosing Spondylitis Functional Index; ASDAS-CRP Ankylosing Spondylitis Disease Activity Score with CRP; ASQOL Ankylosing Spondylitis Quality of Life Questionnaire; PCS Physical Component Summary Sscore; MCS Mental Component Summary Score.; PF Physical Functioning; RP Role Physical; BP Bodily Pain; GH General Health; VT vitality; SF Social Functioning; RE Role Emotional; MH Mental HealthΔ Changing according to basal values at week 24Figure 1.Improvement in disease activity and quality of life during the follow-up timeFigure 2.Mean change in Short Form 36 scores for patients with axial spondyloarthritis following anti-TNF therapyDisclosure of Interests:None declared</jats:sec

AB0469 CLINICAL DISEASE MIGHT BE DIVIDED INTO TWO PHENOTYPES IN ANCA ASSOCIATED VASCULITIS; RESULTS OF A CLUSTER ANALYSIS

Background:One of the controversial matters in ANCA associated vasculitis is the definition of disease based on clinical characteristics since there is remarkable overlap between disease groups. For instance, single organ disease like renal limited vasculitis (RLV) is not take place most of the definitions or classification criteria.Objectives:The aim of this study to determine clinical subgroups that may incorporate different clinical phenotypes including RLV in AAV patients followed up in two tertiary centers.Methods:Baseline clinical features of AAV patients were studied. To analyse our data and identify sub-groups of AAV patients with similar clinical characteristics, a two-step cluster analysis using log-likelihood distance measures was performed. For clustering we evaluated the following variables: gender, age at symptom onset, the presence of major organ involvement (renal, upper and lower respiratory tract, skin, joint, eye) and ANCA specificity.Results:In total 165 (87 [53%] male, age at diagnosis 51.6± 15.2 years) out of 238 (126 [53%] male, age at diagnosis 51.3± 15.6 years) AAV patients included in the analysis. Some of the demographic and clinical characteristics were summarized in the table 1. There are two distinct cluster in AAV patients. Of 78% those AAV patients with MPO/pANCA, 56% with renal involvement and 89% without ENT involvement were in Cluster 1. Of 77% those patients with PR3/cANCA, 89% with arthritis, 74% with eye involvement, 83% with skin, 91% with upper, and 60% with lower respiratory tract involvement and 92% of those without renal disease were in Cluster 2. Most of the (89%) patients classified as MPA and all as RLV were repositioned in Cluster 1 and 74% of GPA and 64% of EGPA patients were in Cluster 2.Table 1.Baseline characteristics of 165patients with AAVAge at diagnosis, mean years ± SD, (n)51.6 ±15.2, 163Male, n (%)87 (52.7)Labaratory results at diagnosisGFR =&lt;60, n (%)100/145 (69)MPO-ANCA or p-ANCA /Pr3-ANCA or c-ANCA68 (41.2)/ 97 (58.8)Variants of AAVn (%)MPA26(15.8)GPA108 (65.5)EGPA11 (6.7)RLV20 (12.1)Organ systems involved at diagnosis n (%)Cutaneous24 (14.5)Eye23 (13.9)Ear, nose and throat90 (54.5)Low respiratory tract111 (67.3)Cardiovascular system5/163 (3.1)Gastrointestinal system10/164 (6.1)Renal129 (78.2)Peripheral nervous system16 (9.7)GFR: glomeruler filtration rate; ANCA: antineutrophil cytoplasmic antibodies; Pr3: proteinase 3; MPO: myeloperoxidase; p-ANCA: perinuclear ANCA; c-ANCA: cytoplasmic ANCA; MPA: Microscopic Polyangiitis; GPA: Granulamatosis and Polyangiitis; EGPA:Eosinophilic Granulomatosis with Polyangiitis; RLV: Renal limited vasculitisConclusion:Patients with AAV could be separated into two distinct categories. PR3 ANCA specificity and more organ/system involvement determine one and MPO ANCA specificity in renal disease define other subgroup.Figure. Determining characteristics of ANCA associated vasculitis clustersFigure.Disclosure of Interests:None declared</jats:sec

AB0865 The Factors affecting patient global assesment in patients with Axial Spondyloarthritis

BackgroundThe BASDAI is one of the basic scales used in the measurement of disease activity in patients with spondyloarthritis and allows the evalution of various aspects of the disease (axial and peripheral disease as well as inflammation). The patient global assesment (PGA) is a one-dimensional scale in which patients evaluate how their illness affects their health.ObjectivesIn this study, we planned to test and review the possible determinants of PGA and its relation with BASDAI components, BASFI scores and disease-related features both at first visit and at the 2 year follow-up.MethodsPatients with axSpA whose baseline BASDAI and PGA scores were complated, were included in the analysis. The demographic, clinical and laboratory characteristics of the patients were recorded. The relation between PGA scores and BASDAI sub-score, BASFI score and other patient and disease characteristics were tested both univariate and multivariate analysis methods. The factors affecting the change in the PGA score over 2-year follow-up were also analyzed with GEE analysis method.ResultsIn total 313 patients (56.5% of male, 61.7% AS, mean age at diagnosis 34.3±11 years) were included in the analysis. Sperman’s rho test was used for correlation analysis. Baseline PGA scores were in correlation with the BASDAI total score (rho:0.71, p&lt;0.001). PGA scores of female patients were found to be significantly higher (p=0.037) and each BASDAI indivual score and BASFI scores were moderately/well correlated with PGA (Table 1). Multivariate analysis revealed that spinal pain (BASDAI Q2), the severity of morning stiffness (BASDAI Q5) and BASFI scores were the main determinants in the global health assesments of patients with axSpA (Table 1). GEE analysis was performed to evaluate the factors affecting the 2 year change in the PGA of the patients, fatigue (BASDAI Q1) (B:1.575, CI%95: [0.241- 2.922]; p=0.021), enthesis (BASDAI Q4) (B:0.888, CI95% [0.049-1.727]; p=0.038) severity of morning stiffness (BASDAI Q5) (B: 2.663, CI%95 [1.447-3.878]; p&lt;0.001),and BASFI scores (B: 2.909, CI95% [1.806-4.011]; p&lt;0.001) were independent determinants of PGA in longitudinal analysis.Table 1.Baseline PGA related factorsSperman AnalysisModel 1Model 2rhopB (%95 CI)pB (%95 CI)psex0.120.037-3.183 (-8.903; 2.538)0.27-3.612 (-9.372; 2.148)0.22BASDAI Q10.59&lt;0.0010.614 (-0.936;2.175)0.440.861 (-0.686; 2.406)0.27BASDAI Q20.66&lt;0.0013.168 (1.536; 4.800)&lt;0.0013.231 (1.587; 4.874)&lt;0.001BASDAI Q30.43&lt;0.0010.619 (-0.613; 1852)0.320.538 (-0.703; 1.779)0.39BASDAI Q40.43&lt;0.0010.374 (-0.741;1.489)0.510.529 (-0.587; 1.645)0.35BASDAI Q50.60&lt;0.0012.088 (0.542; 3.634)0.008BASDAI Q60.43&lt;0.001-0.697(-2.053;0.660)0.31BASDAI (Q5+Q6)/20.56&lt;0.0011.195 (-0.218; 2.608)0.097BASFI0.62&lt;0.0012.097 (0.273-3.921)0.022.263 (0.433; 4.094)0.016BASMI0.28&lt;0.001-0.321 (-1.879;1.237)0.69-0.319(-1.891; 1.253)0.69Serum CRP level0.23&lt;0.0010.066 (-0.100;0.233)0.430.073 (-0.094; 0.241)0.39ConclusionThe study shows that the patients with axSpA mainly rely on morning stiffness and spinal pain in deciding their global health status. Fatigue, enthesis and morning stiffness were found to be effective factors in the PGA changes of the patients under treatment. Although PGA is unidimentional, its well correlation with the BASDAI total score may be another proof of the validity of both scales.Disclosure of InterestsNone declared</jats:sec

AB0456 HYDROXYCHLOROQUINE MIGHT REDUCE MORTALITY IN PATIENTS WITH SYSTEMIC SCLEROSIS

Background:Systemic sclerosis (SSc) is a devastating disease that has a profound impact on life expectancy, reflected by a standardised mortality ratio of 3,5. There is still limited data regarding the predictive factors for mortality in patients with SSc. Determining those factors could guide in disease management and follow up.1Objectives:We aimed to identify the predictive factors for death in SSc.Methods:Patients followed in a tertiary rheumatology clinic in the last 5 years were included in this retrospective study. All of the patients met the ACR / EULAR SSc 2013 criteria. Medical records of the patients were reviewed. Follow up time was defined as the time period from the first admission of the patient to our rheumatology clinic until the date of death or the date on which the study was performed. Candidate predictive factors for mortality were tested by Kaplan-Meier (with Log rank) and Cox-regression analyses.Results:In total 146 patients (mean age 55.6±12.3 years, female 89.7%, diffuse cutaneous type SSc 45.2%) were included in the study (Table 1). The mean age at diagnosis of study group was 48±13.7 years. The median duration of follow up was 71 (6-228) months. Fourteen (10%) patients died during follow-up. The causes of death were: pulmonary (7), renal (2) and cardiac diseases (1), infection (3) and cancer (1).Univariate analysis revealed that age at diagnosis (p=0.028), SSc subtype (p=0.035), the presence of interstitial lung disease (p=0.002), oesophageal involvement (on computed tomography) (p=0.030), pulmonary artery systolic pressure of ≥35 mmHg (measured by transthoracic echocardiography) (p=0.004), glucocorticoid (p=0.029), hydroxychloroquine (p=0.002) and cyclophosphamide (p=0.006) usage at any time were associated with mortality (Figure 1). Multivariate analyses model formed with age at diagnosis (B: 0.055, 95% CI, 1.005-1.112; p=0.033), SSc subtype (B: 0.963, 95% CI 0.541-12.684; p=0.231), glucocorticoid (B: 1.396, 95% CI, 0.487-33.507; p=0.196) and hydroxychloroquine usage (B: -1.50, 95% CI, 0.061-0.816; p=0.023) showed that age at diagnosis and hydroxychloroquine usage were independent predictive factors for mortality in patients with SSc.Conclusion:The results of the study revealed for the first time that apart from the age at diagnosis hydroxychloroquine might reduce mortality in patients with SSc. Further studies are needed to prove of this information.References:[1]Elhai M, et al. Ann Rheum Dis 2017;0:1–9. doi:10.1136/annrheumdis-2017-211448Table 1.The demographic and clinical features in patients with systemic sclerosis.CharacteristicBaselineAge at diagnosis*48±13.7Female sex, n (%)131 (89.7)Duration of follow-up, months**71 (6-228)Disease subtype, n (%)Diffuse / Limited66 (45.2) / 80 (54.8)Autoantibodies, n (%)Anti-Scl70 antibody50/143 (35.0)Anti-Centromere antibody62/143 (43.4)Immunsuppresive medication, ever, n (%)Hydroxychloroquine91/143 (63.6)Mycophenolate mofetil18/145 (12.4)Azathioprine47/145 (32.4)Cyclophosphamide24/145 (16.6)Glucocorticoid80/140 (57.1)Others, n (%)ILD68/130 (52.3)Pericardial effusion, ever26/133 (19.5)Esophageal dilation (detected by CT)51/128 (39.8)sPAP ≥35mmHg, ever (measured by ECHO)46/142 (32.4)*Parameter presented as mean±SD**Parameter presented as median (min-max)CT, computed tomography; ECHO, echocardiogram; ILD, interstitial lung disease; sPAP, systolic pulmonary artery pressureFigure 1.Disclosure of Interests:None declared.</jats:sec

POS1165 Lifestyle And Mood Changes In Axspa Patients During The Quarantine Period

Background:On March 11, 2020, the World Health Organization declared coronavirus disease 2019 (COVID-19) as a pandemic, and mandatory quarantine was applied in Turkey between April and June 2020. With this sanction, sudden changes occurred in a routine lifestyle.Objectives:This study aimed at evaluating physical activity changes, presence of anxiety and depression, altered eating habits and their relationship with disease activity in axial spondyloarthritis (AxSpA) patients during the quarantine period.Methods:AxSpA patients, who were examined in the rheumatology clinic in the last year before the pandemic period and their relatives were included in this study and were contacted by phone to participate. A structured questionnaire form was performed which included the following data: questions about demographic characteristics, medication use, disease activity scales; BASDAI, BASFI, Patient acceptable symptom state (PASS), patient-reported physical activity state, Short Questionnaire to Assess Health enhancing physical activity (SQUASH), Three-Factor Eating Questionnaire (TFEQ-21), and Hospital Anxiety and Depression Scale (HADs).Results:204 AxSpA patients and 106 patients’ relatives were contacted in the study (Figure 1). The frequency of male sex and alcohol consumption was higher in the AxSpA compared to the relatives and, other demographic features were summarized in Table 1. 30% of AxSpA patients and 37% of patient relatives were gained weight with mean 4.5±2.4 and 4.4±3.4 kilograms, respectively. Weight gain were similar male and female in AxSpA (26.2% vs 37.2%, p&gt;0.05). However, the men in the AxSpA group gained more weight than relatives group (26.2% vs 7%, p&lt;0.05). Weight gain group had decreased physical activity than stable group in AxSpA patients (54.8% vs 37.8%, p&lt;0.05). We showed mild negative correlation between BASDAI and BASFI scores with SQUASH- total activity score (r:-0.15, p&lt;0.05; r:-0.25, p&lt;0.001, respectively). Anxiety prevalence were found slightly higher in patients group but not significantly (40.2% vs 32.1%; p&gt;0.05). Depression were much higher in AxSpA group than relatives (43.6% vs 28%, p&lt;0.001). Depression and anxiety were correlated with disease activity (HADs Depression vs BASDAI r:0.380, p&lt;0.001; HADs Anxiety vs BASDAI r:0.418, p&lt;0.001) and function (HADs Depression vs BASFI r:0.342, p&lt;0.001; HADs Anxiety vs BASFI r:0.313, p&lt;0.001). Among eating habits, uncontrolled and emotional eating scores were showed low correlation with anxiety (r:0.169, p&lt;0.05; r:0.163, p&lt;0.05, respectively).Conclusion:One third of our patients were weight gain and approximately half of them had decreased physical activity but we did not show relation between these parameters and disease related factors in the limited period. In addition to that depression and anxiety were detected significant part of AxSpA patients and both of them were correlated with disease activity.Table 1.Study Population CharacteristicsAxSpa n:204 Controls n:106 p valueAge (years) mean ± SD43.1±11.440.6±12.6&gt;0.05Male n(%)125(61.3)26(24.5)&lt;0.001Education time (years) mean ± SD9.8±4.39.7±4.0&gt;0.05Current smoker n(%)77(37.7)31(29.2)&gt;0.05Alcohol consumption n(%)60(29.4)9(8.5)&lt;0.001Current BMI kg/m2 mean ± SD26.8±4.626.5±4.7&gt;0.05Weight gain group n(%)62 (30.4)40(37.7)&gt;0.05Weight stable group n(%)142 (69.6)66(62.3)Current BASDAI mean ± SD1.8±1.5N/ACurrent BASFI mean ± SD1.5±1.8N/APatients treated with biologic drugs n(%)118(57.8)N/APatients treated with conventional drugs n(%)84(41.1)N/APresence of Anxiety n(%)82(40.2)34(32.1)&gt;0.05Presence of Depression n(%)89(43.6)30(28.0)&lt;0.001TFEQ-R21emotional eating mean ± SD5.2±3.15.6±2.7&lt;0.05TFEQ-R21uncontrolled eating mean ± SD14.7±6.317.5±5.4&lt;0.001TFEQ-R21cognitive restraint mean ± SD14.3±4.315±4.2&gt;0.05Stable physical activity n(%)117(57.4)49(46.2)&gt;0.05Decreased physical activity n(%)87(42.6)57(53.8)Acknowledgements:Special thanks to our clinical nurse Alev Vayni for her devoted assistance in interviewing patients to fill out the questionaire.Disclosure of Interests:None declared.</jats:sec

AB0669 DEPRESSION AND ANXIETY MIGHT NOT BE INCREASED DURING COVID-19 PANDEMIC IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS

Background:Anxiety and depression are most common psychiatric disorders in chronic inflammatory rheumatic condition as well as axial spondyloarthritis (axSpA) (1). The prevalence of depression has been reported as 11-64% depending on the criteria used. Also self-reported depression and anxiety were found to be associated with disease activity and function in axSpA (1,2). It is observed that mental health is affected among healthy subjects during the COVID-19 pandemic, but this condition has not been systematically reviewed in axSpA patients.Objectives:We aimed to compare frequency of self-reported depression and anxiety before and during the Covid-19 pandemic in patients with axSpA.Methods:Seventy-six axSpA patients who were evaluated for the presence of depression and anxiety by using Hospital Anxiety and Depression scale (HADs) before pandemic were included in this study. All participants were classified according to the ASAS axSpA classification criteria. Patients were contacted by phone to participate and complete the HADS questionnaire. Demographic and disease related characteristics including BASDAI, BASFI and Patient Acceptable Symptom State (PASS) were recorded during interview. The HADs cut off value was taken as &gt;7 in both groups to define the presence of anxiety or depression. Before and during pandemic period anxiety and depression scores were statistically compared.Results:The demographic and disease related characteristics of axSpA patients with and without anxiety/depression were summarized in Table 1. The frequency of anxiety (43.4% vs %43.4; p&gt;0.05) and depression (46.1% vs 44.7%; p&gt;0.05) were found to be similar before and during pandemic period. Patients with anxiety (HADs&gt;7) and depression (HADs&gt;7) had higher BASDAI and BASFI scores and much less PASS positivity (Table 1). Although the frequency of depression was similar between before and during the pandemic period, symptom severity in depression was slightly increased during the pandemic (Figure 1).Table 1.Patients’ demographics and characteristics according to the presence of anxiety and depressionVariablesPresence of depressionn:35Absence of depressionn:41PPresence of anxiety n:33Absence of anxiety n:43PAge (years) mean ± SD41.8±11.244.1±9.3&gt;0.0542.0±10.943.6±10.0&gt;0.05Male n(%)21(60.0)26(63.4)&gt;0.0518(54.5)29(67.4)&gt;0.05Education time (years) mean ± SD9.6±4.811.0±4.2&gt;0.059.7±5.010.6±4.1&gt;0.05Current smoker n(%)18(51.4)15(36.6)&gt;0.0515(45.5)18(41.9)&gt;0.05Alcohol consumption n(%)12(34.3)12(29.3)&gt;0.0510(30.3)14(32.6)&gt;0.05Current BMI kg/m2 mean ± SD26.0±4.826.8±4.5&gt;0.0526.4±5.026.5±4.3&gt;0.05Sleep time (hours) mean ± SD7.6±1.77.6±1.3&gt;0.057.5±1.67.7±1.4&gt;0.05Current BASDAI mean ± SD2.5±1.61.4±1.6&lt;0.052.7±1.81.3±1.3&lt;0.001Current BASFI mean ± SD2.4±2.11.1±1.3&lt;0.052.4±2.01.2±1.4&lt;0.05PASS positivity n(%)16(45.7)29(70.7)&lt;0.0514(42.4)31(72.1)&lt;0.05Current depression and anxiety scores were correlated with disease activity (HADs Depression vs BASDAI r:0.530, p&lt;0.001; HADs Anxiety vs BASDAI r:0.500, p&lt;0.001) and function (HADs-Depression vs BASFI r:0.519, p&lt;0.001; HADs-Anxiety vs BASFI r:0.391, p&lt;0.001). These relationships were also observed in the pre-pandemic period (HADs-Depression vs BASFI r:0.326, p&lt;0.05; HADs-Anxiety vs BASDAI r:0.342, p&lt;0.05).Conclusion:Depression and anxiety symptoms seems to be comparable before and after the COVID-19 pandemic. Regardless of this period, the presence of both depression and anxiety are associated with disease activity, function and less patient acceptable symptom state.References:[1]Zhao S, Thong D, Miller N, et al. The prevalence of depression in axial spondyloarthritis and its association with disease activity: a systematic review and meta-analysis. Arthritis Res Ther. 2018;20:140.[2]Barişan E, Bayir D, Solmaz D. Aksiyel spondiloartrit hastalarinda anksiyete düzeyinin çeşitli ölçeklerle değerlendirilmesi ve anksiyete ile ilişkili faktörler. Dokuz Eylül Üniversitesi Tip Fakültesi Dergisi. 2019; 129-137.Figure 1.Disclosure of Interests:None declared</jats:sec